After an initial shock to the system last spring, life sciencescompanies are accelerating R&D activity, which is driving newdemand for lab research facilities, according to ColliersInternational Life Sciences.
"In many cases, this pivot to COVID-related initiatives hasincreased the activity, staffing and demand for lab space," thecompany said in a mid-year update.
When stay-at-home orders began issuing last March, drugdevelopment companies at first restricted non-critical activitiesas they tried to forecast the new rules of engagement. Since then,public and private investment has been rolling in as the FDA tracksnumerous active trials of vaccines, therapeutic agents anddiagnostics for COVID-19. "If anything, the Life Sciences sectorhas recovered from the shock and accelerated more quickly thananticipated," Colliers reports.
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
*May exclude premium content
Already have an account?
Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Scott Graham
Scott Graham focuses on intellectual property and the U.S. Court of Appeals for the Federal Circuit. He writes ALM's Skilled in the Art IP briefing. Contact him at [email protected].
